{"DataElement":{"publicId":"6644365","version":"1","preferredName":"Prior Therapeutic Procedure Adverse Event Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to prior therapeutic agents and outcomes of adverse events as outlined in the study protocol.","longName":"PRTX_AE_RCVRY_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6644364","version":"1","preferredName":"Prior Therapeutic Procedure Adverse Event Recovery Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s)._A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"3693401v1.0:5477143v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"3693401","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D743B17B-E51D-394C-E040-BB89AD4312FF","latestVersionIndicator":"Yes","beginDate":"2013-03-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2013-03-06","modifiedBy":"ONEDATA","dateModified":"2013-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5477143","version":"1","preferredName":"Adverse Event Recovery Clinical Trial Eligibility Criteria","preferredDefinition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).:A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C41331:C25746:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recovery","conceptCode":"C25746","definition":"A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D081384-C3D9-5D63-E053-F662850A98A8","latestVersionIndicator":"Yes","beginDate":"2016-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-21","modifiedBy":"ONEDATA","dateModified":"2016-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F136AD-A7C5-2D20-E053-F662850A40B3","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-15","modifiedBy":"SOKKERL","dateModified":"2019-06-17","changeDescription":"2/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has patient failed to recover","type":"Preferred Question Text","description":"Has patient failed to recover from AEs due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1), with the exception of alopecia and endocrinopathies from prior immunotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., may not have residual toxicities greater than grade 1 or above baseline), excluding alopecia or has endocrinopathies associated with prior immunotherapy treatment but which are controlled with replacement therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient failed to recover to grade 1 from treatment related adverse events due to prior anti-cancer therapy (except alopecia)?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Have non-hematologic adverse events of prior chemotherapy, surgery, or radiotherapy, except alopecia, failed to resolve to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade less than or equal to 2 prior to starting therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has patient failed to recover from AEs due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1), with the exception of alopecia and grade 1-2 taxane-induced neuropathy?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has patient failed to recover to baseline from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 unless the AEs are clinically nonsignificant and/or stable on supportive therapy, with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient failed to recover from AEs due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1), with the exception of less than or equal to Grade 2 neuropathy and alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Patient has not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1) with the exceptions of alopecia and endocrinopathies from prior immunotherapy-based treatments that are well controlled with hormone replacement?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1), with the exception of alopecia and lymphopenia (any grade permitted) or residual peripheral neuropathy grade 2 or better?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient failed to recover from AEs grade 2 or higher from previous anti-cancer therapy, except alopecia, at the time of randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e. have residual toxicities greater than Grade 1, with the exception of alopecia and lymphopenia?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), with the exception of alopecia and neuropathy?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient failed to recover from immune related adverse events due to prior therapy (i.e., have residual toxicities greater than Grade 1) with the exception of hypothyroidism managed by supplemental levothyroxine?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (including ongoing sensory or motor neuropathy of Grade 2 or higher) (i.e., have residual toxicities greater than Grade 1 or returned to baseline) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior systemic anti-cancer therapy (i.e., have residual toxicities greater than Grade 1 of the CTCAE v5, pre-treatment baseline or to a level permitted under other sections of Inclusion/Exclusion criteria) with the exception of alopecia or electrolyte abnormalities that can be corrected to less than or equal to Grade 1 prior to treatment initiation?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1), except for less than or equal to Grade 2 neuropathy or less than or equal to Grade 2 alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1)?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), with the exception of alopecia, or stable chronic grade 2 toxicities that do not overlap with presumed toxicities of entinostat or ZEN003694?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient failed to recover from AEs due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1), with the exception of alopecia and peripheral neuropathy?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient failed to recover from AEs due to prior systemic anti-cancer therapy (i.e., have residual toxicities greater than grade 1), with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient failed to recover from grade greater than or equal to 2 adverse events due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient had chemotherapy, has patient failed to fully recover organ and marrow function following the nadir of the last chemotherapy cycle?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia, controlled endocrine toxicity (e.g., hypothyroidism), and cutaneous toxicity which will be permitted at Grade 2?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events of previously administered therapeutic agents (i.e., have residual toxicities greater than Grade 2) according to CTCAE 5.0, with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Has patient failed to recover from clinically significant adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Has patient failed to recover from clinically significant adverse events of their most recent cancer immunotherapy to grade 1 or less (with the exception for alopecia or lymphopenia)?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia, stable hyperthyroidism on replacement therapy, type-1 diabetes, well-controlled insulin, and non-clinically significant toxicities at the discretion of the study Principal Investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia and neuropathy, which may be less than or equal to grade 2?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F136AD-A7DF-2D20-E053-F662850A40B3","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-15","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeDescription":"2/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}